Aditxt, Inc. Warrant, Exercise Price, Decrease
Aditxt, Inc. (ADTX) reported Warrant, Exercise Price, Decrease of $18.63 per share for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Notes › Equity › Stockholders' Equity Note
us-gaap:WarrantExercisePriceDecrease · last filed 2026-05-20
- Aditxt, Inc. warrant, exercise price, decrease for the quarter ending 2026-03-31 was $18.63.
- Aditxt, Inc. warrant, exercise price, decrease for the quarter ending 2023-03-31 was $1.55.
- Aditxt, Inc. warrant, exercise price, decrease for the quarter ending 2020-09-30 was $5.00.
| Period end | Warrant, Exercise Price, Decrease | Warrant, Exercise Price, Decrease 0 month | Warrant, Exercise Price, Decrease 1 month | Warrant, Exercise Price, Decrease 3 month | Warrant, Exercise Price, Decrease 6 month |
|---|---|---|---|---|---|
| 2026-03-31 | $18.63 10-Q · filed 2026-05-20 | ||||
| 2023-08-31 | $12.50 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | $1.55 10-Q · filed 2023-08-14 | ||||
| 2023-03-31 | $1.55 10-Q · filed 2023-05-15 | ||||
| 2022-08-01 | $11.78 10-Q · filed 2022-11-14 | ||||
| 2022-06-15 | $57.50 10-K · filed 2023-04-17 | ||||
| 2021-08-31 | $3000.00 10-Q · filed 2024-05-20 | ||||
| 2021-01-25 | $4.00 10-K · filed 2022-03-31 | ||||
| 2020-09-30 | $5.00 10-Q · filed 2020-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |